BioPharma Dive Quotes Shanghai Life Sciences Partner on China FDA Draft Guidelines
Life sciences partner Katherine Wang (Shanghai) was quoted in an April 3 article in BioPharma Dive on draft guidelines issued by the China Food and Drug Administration (CFDA) that would make the China market more drug-friendly.
Ms. Wang explains that the draft guidelines indicated the CFDA's general direction of encouraging innovative assets to come to China earlier. Companies can expect the CFDA to prioritize their resources for innovative drugs, which is good news for multinational companies. But the CFDA is also focusing on enhancing the quality of generic drugs, which can be a challenge for multinationals because the Chinese government wants to encourage hospital procurement of generic drugs. She notes that there is still a preference for drugs made in China, so the more companies can localize their operations in China, the better they may be treated during the market access stage.